The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.22 HKD | +2.50% | +11.96% | +9.26% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.26% | 13.03B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets